Target capture neutralizing antibodies (NAbs) to rituximab are anti-drug antibodies (ADAs) that specifically inhibit rituximab’s pharmacological activity by preventing its binding to the CD20 antigen on B-lymphocytes. These NAbs can compromise therapeutic efficacy by sterically hindering the interaction or downstream signaling required for B-cell lysis, a key mechanism of action for rituximab. In some cases, NAbs may also cross-react with endogenous proteins, potentially impairing essential immune functions and triggering adverse effects.
In clinical and research settings, detecting and quantifying NAbs to rituximab is crucial for evaluating treatment response, guiding dosing strategies, and assessing immunogenicity risk. The SHIKARI® T-CAP NAb Assay provides a competitive ligand binding platform to monitor NAb presence by measuring drug-target interaction interference. A reduction in signal indicates the presence of NAbs that inhibit rituximab’s binding ability. These assays are used alongside ADA screening to ensure comprehensive immunogenicity assessment during biologic drug development and post-market surveillance.
From a biomarker perspective, the presence of rituximab-specific NAbs serves as a predictive indicator for altered pharmacokinetics, reduced therapeutic benefit, or potential hypersensitivity reactions. Monitoring these antibodies supports therapeutic drug monitoring (TDM) protocols, ensuring optimal patient outcomes through individualized treatment plans and early identification of drug resistance or adverse immune responses.
This product is manufactured in Turkey by Matriks Biotek.